Evidence Review
Metabolic Effects in Type 2 Diabetes
The two most rigorous cashew-specific RCTs were both conducted in people with type 2 diabetes, where dietary interventions tend to show larger effects.
Mohan et al. (2018, PMID 29378038) conducted a 12-week parallel-arm RCT in 300 Asian-Indian adults with T2D, randomly assigned to a standard diabetic diet or the same diet plus 30g/day of unsalted cashews. The cashew group showed a significantly greater increase in plasma HDL cholesterol (p=0.033) and a significantly greater reduction in systolic blood pressure (−5.7 vs −2.4 mmHg, p=0.034). There were no significant between-group differences in LDL cholesterol, total cholesterol, triglycerides, fasting blood glucose, HbA1c, or body weight. The selective improvement in HDL and blood pressure without broad lipid disruption is consistent with cashews' oleic acid and magnesium content — both known to support vascular function [1].
Damavandi et al. (2019, PMID 30881468) randomized 50 T2D patients to either a control diet or an isocaloric diet in which 10% of total daily calories were replaced with cashews for 8 weeks. The cashew group showed significantly reduced serum insulin (p=0.027), reduced LDL-C/HDL-C ratio (p=0.043), and lower malondialdehyde — a marker of lipid peroxidation and oxidative stress. The improvement in the atherogenic ratio without directly lowering LDL may reflect improved HDL function and reduced oxidation of existing LDL particles [2].
Lipid Effects in Generally Healthy Adults
Baer and Novotny (2019, PMID 30753323) conducted a highly controlled 4-week crossover RCT in generally healthy adults consuming 1.5 servings of cashews per day on top of a standardized base diet. Compared to the nut-free phase, cashew consumption produced no significant changes in LDL, HDL, total cholesterol, triglycerides, blood pressure, or inflammatory markers. The study was rigorously controlled with provided meals. The finding does not undermine cashews' value — it indicates that in people with already-healthy lipid profiles, there is no additional lipid benefit, and importantly no harm [3].
Broader Nut and Cardiovascular Mortality Evidence
Becerra-Tomás et al. (2019, PMID 31361320) published a systematic review and dose-response meta-analysis of 19 prospective cohort studies examining nut consumption and cardiovascular outcomes. Higher total nut consumption was associated with a relative risk of 0.77 (95% CI: 0.72–0.82) for CVD mortality — a 23% reduction — and similar inverse associations for CHD and stroke outcomes. The dose-response relationship was approximately log-linear, with benefits accumulating at modest intakes (around 28g/day, or one ounce). While cashews were not isolated, this meta-analysis provides the population-level context confirming that nut-eating patterns confer meaningful cardiovascular protection [4].
Prebiotic Effects on Gut Microbiota
Menezes et al. (2021, PMID 33934170) used a validated human colonic fermentation model to assess cashew by-product fiber. Compared to a cellulose control, cashew material significantly increased lactic acid bacteria counts (p<0.05), decreased Enterobacteriaceae counts (p<0.05), lowered fermentation pH (reflecting organic acid production), and increased acetic, propionic, and butyric acid concentrations. The increase in butyrate is especially noteworthy given butyrate's established role in colonocyte metabolism and gut barrier maintenance. These effects were observed in vitro and need validation in human feeding trials, but the findings align with the known prebiotic behavior of the fiber and polyphenol compounds (including catechins) found in cashews [5].
Brazilian Nuts Study (2024)
Meneguelli et al. (2024, PMID 38988854) conducted a three-arm RCT — whole cashew nuts, cashew nut oil, and a control group — in adults undergoing a weight-loss dietary intervention. Both cashew groups showed reductions in cardiovascular risk factors including blood pressure and cardiometabolic markers compared to the control group, providing some of the most recent evidence that cashew consumption provides cardiometabolic benefits in a clinical intervention context, even when the primary goal is weight management [6].
Strength of Evidence and Limitations
The cashew-specific human trial evidence is strongest for the T2D population and modest for healthy adults. Most trials are short (4–12 weeks) and small (50–300 participants), limiting long-term conclusions. The prebiotic evidence is entirely in vitro. The broader nut-consumption literature is large and consistent but treats cashews as part of a category rather than isolating their effects.
Taken together, the evidence supports including cashews as a regular part of a whole-food diet, with the clearest benefits for those managing blood sugar, blood pressure, and cardiovascular risk. They are among the most nutrient-dense snack options available, particularly for copper and magnesium, and belong in the same evidence-supported food category as walnuts, almonds, and other tree nuts with established cardiovascular benefit.